他克莫司血药浓度时间加权变异度与低药物暴露联合与肾移植后移植物生存的关联
该回顾性队列研究纳入2000年1月1日至2013年9月29日在Rabin医疗中心接受肾移植并接受他克莫司治疗的803例患者,评估移植早期时间加权变异度(TWCV)与移植物生存的关联。高TWCV三分位与移植物生存降低相关(多因素HR 1.74,95%CI 1.14-2.63,P=0.01),高TWCV与低药物暴露(<5 ng/mL)的交互作用显著(P=0.004),该组合患者移植物生存降低(多因素HR 2.6,95%CI 1.65-4.11,P<0.001)。
要点
- 高TWCV三分位与移植物生存降低独立相关(多因素HR 1.74,95%CI 1.14-2.63,P=0.01)。
- 高TWCV与低药物暴露(<5 ng/mL)的交互作用与移植物生存降低显著相关(P=0.004)。
- 高TWCV合并低药物暴露者130例(16.2%),移植物生存降低(多因素HR 2.6,95%CI 1.65-4.11,P<0.001)。
核心结论
- 高TWCV与低药物暴露的组合可能识别移植早期的高风险患者。
研究设计与样本
- 回顾性队列研究,纳入2000年1月1日至2013年9月29日在Rabin医疗中心接受肾移植并接受他克莫司治疗的全部患者,共803例。
- TWCV定义为时间加权标准差除以平均药物浓度。
- 采用单因素和多因素Cox比例风险模型,主要结局为患者和移植物生存。
主要发现
- 高TWCV三分位与移植物生存降低相关:单因素分析HR 1.69(95%CI 1.14-2.53,P=0.01),多因素分析HR 1.74(95%CI 1.14-2.63,P=0.01)。
- 高TWCV与低药物暴露的交互作用与移植物生存降低显著相关(P=0.004),而高TWCV与高药物浓度的交互作用不显著。
- 130例(16.2%)患者具有高TWCV合并低药物浓度(<5 ng/mL),其移植物生存降低:单因素分析HR 2.42(95%CI 1.57-3.74,P<0.001),多因素分析HR 2.6(95%CI 1.65-4.11,P<0.001)。
关键数值与推荐
- 高TWCV三分位:多因素HR 1.74(95%CI 1.14-2.63,P=0.01)。
- 高TWCV合并低药物浓度(<5 ng/mL):多因素HR 2.6(95%CI 1.65-4.11,P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The variability of tacrolimus blood levels has been shown to be associated with inferior graft survival. However, the effect of variability during the early post-transplantation period has not been evaluated. We sought to evaluate the association between time-weighted variability in the early post-transplantation period and graft survival. We also explored the interaction between drug level variability and exposure to inadequate drug levels. METHODS: This retrospective cohort study included all patients who underwent kidney transplantation in the Rabin Medical Center and were treated with tacrolimus. Time-weighted coefficient of variability (TWCV) was defined as time-weighted standard deviation divided by the mean drug level. Univariate and multivariate Cox proportional hazard model was used with the primary outcome of patients and graft survival. RESULTS: The study population included 803 patients who underwent kidney transplantation between 1 January 2000 and 29 September 2013. The high tertile of TWCV of tacrolimus blood levels was associated with reduced graft survival by univariate and multivariate analyses [hazard ratio (HR) 1.69, 95% confidence interval (CI) 1.14-2.53, P = 0.01 and HR 1.74, 95% CI 1.14-2.63, P = 0.01, respectively]. The interaction between high TWCV and exposure to inadequately low drug levels was significantly associated with reduced survival (P = 0.004), while the interaction between TWCV and high drug blood levels was not. One hundred and thirty patients (16.2%) had the combination of high TWCV and exposure to low drug values (<5 ng/mL). These patients had reduced graft survival by univariate and multivariate analyses (HR 2.42, 95% CI 1.57-3.74, P < 0.001 and HR 2.6, 95% CI 1.65-4.11, P < 0.001, respectively). CONCLUSIONS: The combination of high TWCV and exposure to low drug levels might identify high-risk patients in the early post-transplantation period.
引用
- Rozen-Zvi B, Schneider S, Lichtenberg S, et al. Association of the combination of time-weighted variability of tacrolimus blood level and exposure to low drug levels with graft survival after kidney transplantation. Nephrol Dial Transplant. 2017. PMID: 28025383. doi:10.1093/ndt/gfw394
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。